A Phase 3 interventional study of B/F/TAF in HIV-1 Infection, sponsored by Gilead Sciences. Completed at 25 sites in 5 countries. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2020-12-01.
Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objective of this study is to characterize the virologic efficacy of switching virologically suppressed participants on an elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) fixed-dose combination (FDC) regimen or a tenofovir disoproxil fumarate (TDF) containing regimen to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) FDC.
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/ Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
B/F/TAF FDC for at least 96 weeks.
Drug: B/F/TAF
Drug pages: Bictegravir · Emtricitabine · Tenofovir alafenamide
50/200/25 mg FDC tablet administered orally once daily without regard to food.
Also known as: Biktarvy®
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24 as Defined by the Food and Drug Administration (FDA)-Defined Snapshot Algorithm
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defined a participant's virologic response status using only the viral load at the predefined timepoint within an allowed window of time, along with study drug discontinuation status.
Time frame: Week 24
Percentage of Participants Experiencing Adverse Events (AEs) Through Week 24
An AE was any untoward medical occurrence in a clinical study participant administered a medicinal product, which did not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. AEs may also included pre- or post-treatment complications that occurred as a result of protocol specified procedures, lack of efficacy, overdose, drug abuse/misuse reports, or occupational exposure. Preexisting events that increased in severity or changed in nature during or as a consequence of participation in the clinical study were also considered AEs.
Time frame: First dose date up to Week 24
Percentage of Participants Experiencing AEs Through Week 48
An AE was any untoward medical occurrence in a clinical study participant administered a medicinal product, which did not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. AEs may also included pre- or post-treatment complications that occurred as a result of protocol specified procedures, lack of efficacy, overdose, drug abuse/misuse reports, or occupational exposure. Preexisting events that increased in severity or changed in nature during or as a consequence of participation in the clinical study were also considered AEs.
Time frame: First dose date Up to Week 48
Percentage of Participants Experiencing AEs Through Week 72
An AE was any untoward medical occurrence in a clinical study participant administered a medicinal product, which did not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. AEs may also included pre- or post-treatment complications that occurred as a result of protocol specified procedures, lack of efficacy, overdose, drug abuse/misuse reports, or occupational exposure. Preexisting events that increased in severity or changed in nature during or as a consequence of participation in the clinical study were also considered AEs.
Time frame: First dose date Up to Week 72
Percentage of Participants Experiencing AEs Through Week 96
An AE was any untoward medical occurrence in a clinical study participant administered a medicinal product, which did not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. AEs may also included pre- or post-treatment complications that occurred as a result of protocol specified procedures, lack of efficacy, overdose, drug abuse/misuse reports, or occupational exposure. Preexisting events that increased in severity or changed in nature during or as a consequence of participation in the clinical study were also considered AEs.
Time frame: First dose date Up to Week 96
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Defined by the FDA-Defined Snapshot Algorithm
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defined a participant's virologic response status using only the viral load at the predefined timepoint within an allowed window of time, along with study drug discontinuation status.
Time frame: Week 48
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 72 as Defined by the FDA-Defined Snapshot Algorithm
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 72 was analyzed using the snapshot algorithm, which defined a participant's virologic response status using only the viral load at the predefined timepoint within an allowed window of time, along with study drug discontinuation status.
Time frame: Week 72
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 96 as Defined by the FDA-Defined Snapshot Algorithm
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 96 was analyzed using the snapshot algorithm, which defined a participant's virologic response status using only the viral load at the predefined timepoint within an allowed window of time, along with study drug discontinuation status.
Time frame: Week 96
Change From Baseline in CD4 Cell Count at Week 24
Time frame: Baseline, Week 24
Change From Baseline in CD4 Cell Count at Week 48
Time frame: Baseline, Week 48
Change From Baseline in CD4 Cell Count at Week 72
Time frame: Baseline, Week 72
Change From Baseline in CD4 Cell Count at Week 96
Time frame: Baseline, Week 96
Change From Baseline in CD4 Percentage at Week 24
Time frame: Baseline, Week 24
Change From Baseline in CD4 Percentage at Week 48
Time frame: Baseline, Week 48
Change From Baseline in CD4 Percentage at Week 72
Time frame: Baseline, Week 72
Change From Baseline in CD4 Percentage at Week 96
Time frame: Baseline, Week 96
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24, as Analyzed by Missing = Failure Approach
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 24 was analyzed using missing = failure approach. In this approach, all missing data were treated as HIV-1 RNA ≥ 50 copies/mL.
Time frame: Week 24
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48, as Analyzed by Missing = Failure Approach
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using missing = failure approach. In this approach, all missing data were treated as HIV-1 RNA ≥ 50 copies/mL.
Time frame: Week 48
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 72, as Analyzed by Missing = Failure Approach
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 72 was analyzed using missing = failure approach. In this approach, all missing data were treated as HIV-1 RNA ≥ 50 copies/mL.
Time frame: Week 72
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 96, as Analyzed by Missing = Failure Approach
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 96 was analyzed using missing = failure approach. In this approach, all missing data were treated as HIV-1 RNA ≥ 50 copies/mL.
Time frame: Week 96
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24, as Analyzed by Missing = Excluded Approach
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 24 was analyzed using missing = excluded approach. In this approach, all missing data were excluded in the computation of the percentages (ie, missing data points were excluded from both the numerator and denominator in the computation).
Time frame: Week 24
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48, as Analyzed by Missing = Excluded Approach
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using missing = excluded approach. In this approach, all missing data were excluded in the computation of the percentages (ie, missing data points were excluded from both the numerator and denominator in the computation).
Time frame: Week 48
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 72, as Analyzed by Missing = Excluded Approach
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 72 was analyzed using missing = excluded approach. In this approach, all missing data were excluded in the computation of the percentages (ie, missing data points were excluded from both the numerator and denominator in the computation).
Time frame: Week 72
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 96, as Analyzed by Missing = Excluded Approach
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 96 was analyzed using missing = excluded approach. In this approach, all missing data were excluded in the computation of the percentages (ie, missing data points were excluded from both the numerator and denominator in the computation).
Time frame: Week 96
Participants were enrolled at study sites in Europe. The first participant was screened on 01 March 2018. The last study visit occurred on 29 May 2020.
| Milestone | B/F/TAF |
|---|---|
| Started | 86 |
| Completed | 78 |
| Not completed | 8 |
| Withdrew: Adverse event | 3 |
| Withdrew: Death | 2 |
| Withdrew: Withdrawal by subject | 1 |
| Withdrew: Lost to follow-up | 2 |
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defined a participant's virologic response status using only the viral load at the predefined timepoint within an allowed window of time, along with study drug discontinuation status.
| percentage of participants | B/F/TAF |
|---|---|
| Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24 as Defined by the Food and Drug Administration (FDA)-Defined Snapshot Algorithm | 97.7 |
An AE was any untoward medical occurrence in a clinical study participant administered a medicinal product, which did not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. AEs may also included pre- or post-treatment complications that occurred as a result of protocol specified procedures, lack of efficacy, overdose, drug abuse/misuse reports, or occupational exposure. Preexisting events that increased in severity or changed in nature during or as a consequence of participation in the clinical study were also considered AEs.
| percentage of participants | B/F/TAF |
|---|---|
| Percentage of Participants Experiencing Adverse Events (AEs) Through Week 24 | 62.8 |
An AE was any untoward medical occurrence in a clinical study participant administered a medicinal product, which did not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. AEs may also included pre- or post-treatment complications that occurred as a result of protocol specified procedures, lack of efficacy, overdose, drug abuse/misuse reports, or occupational exposure. Preexisting events that increased in severity or changed in nature during or as a consequence of participation in the clinical study were also considered AEs.
| percentage of participants | B/F/TAF |
|---|---|
| Percentage of Participants Experiencing AEs Through Week 48 | 81.4 |
An AE was any untoward medical occurrence in a clinical study participant administered a medicinal product, which did not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. AEs may also included pre- or post-treatment complications that occurred as a result of protocol specified procedures, lack of efficacy, overdose, drug abuse/misuse reports, or occupational exposure. Preexisting events that increased in severity or changed in nature during or as a consequence of participation in the clinical study were also considered AEs.
| percentage of participants | B/F/TAF |
|---|---|
| Percentage of Participants Experiencing AEs Through Week 72 | 94.2 |
An AE was any untoward medical occurrence in a clinical study participant administered a medicinal product, which did not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. AEs may also included pre- or post-treatment complications that occurred as a result of protocol specified procedures, lack of efficacy, overdose, drug abuse/misuse reports, or occupational exposure. Preexisting events that increased in severity or changed in nature during or as a consequence of participation in the clinical study were also considered AEs.
| percentage of participants | B/F/TAF |
|---|---|
| Percentage of Participants Experiencing AEs Through Week 96 | 95.3 |
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defined a participant's virologic response status using only the viral load at the predefined timepoint within an allowed window of time, along with study drug discontinuation status.
| percentage of participants | B/F/TAF |
|---|---|
| Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Defined by the FDA-Defined Snapshot Algorithm | 90.7 |
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 72 was analyzed using the snapshot algorithm, which defined a participant's virologic response status using only the viral load at the predefined timepoint within an allowed window of time, along with study drug discontinuation status.
| percentage of participants | B/F/TAF |
|---|---|
| Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 72 as Defined by the FDA-Defined Snapshot Algorithm | 94.2 |
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 96 was analyzed using the snapshot algorithm, which defined a participant's virologic response status using only the viral load at the predefined timepoint within an allowed window of time, along with study drug discontinuation status.
| percentage of participants | B/F/TAF |
|---|---|
| Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 96 as Defined by the FDA-Defined Snapshot Algorithm | 74.4 |
| cells/µL | B/F/TAF |
|---|---|
| Change From Baseline in CD4 Cell Count at Week 24 | 20 ± 141.8 |
| cells/µL | B/F/TAF |
|---|---|
| Change From Baseline in CD4 Cell Count at Week 48 | 8 ± 174.8 |
| cells/µL | B/F/TAF |
|---|---|
| Change From Baseline in CD4 Cell Count at Week 72 | 36 ± 145.7 |
| cells/µL | B/F/TAF |
|---|---|
| Change From Baseline in CD4 Cell Count at Week 96 | 22 ± 150.9 |
| percentage of lymphocytes | B/F/TAF |
|---|---|
| Change From Baseline in CD4 Percentage at Week 24 | 0.1 ± 3.52 |
| percentage of lymphocytes | B/F/TAF |
|---|---|
| Change From Baseline in CD4 Percentage at Week 48 | 0.1 ± 3.89 |
| percentage of lymphocytes | B/F/TAF |
|---|---|
| Change From Baseline in CD4 Percentage at Week 72 | -0.1 ± 4.29 |
| percentage of lymphocytes | B/F/TAF |
|---|---|
| Change From Baseline in CD4 Percentage at Week 96 | -0.1 ± 4.34 |
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 24 was analyzed using missing = failure approach. In this approach, all missing data were treated as HIV-1 RNA ≥ 50 copies/mL.
| percentage of participants | B/F/TAF |
|---|---|
| Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24, as Analyzed by Missing = Failure Approach | 97.7 |
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using missing = failure approach. In this approach, all missing data were treated as HIV-1 RNA ≥ 50 copies/mL.
| percentage of participants | B/F/TAF |
|---|---|
| Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48, as Analyzed by Missing = Failure Approach | 90.7 |
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 72 was analyzed using missing = failure approach. In this approach, all missing data were treated as HIV-1 RNA ≥ 50 copies/mL.
| percentage of participants | B/F/TAF |
|---|---|
| Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 72, as Analyzed by Missing = Failure Approach | 94.2 |
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 96 was analyzed using missing = failure approach. In this approach, all missing data were treated as HIV-1 RNA ≥ 50 copies/mL.
| percentage of participants | B/F/TAF |
|---|---|
| Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 96, as Analyzed by Missing = Failure Approach | 79.1 |
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 24 was analyzed using missing = excluded approach. In this approach, all missing data were excluded in the computation of the percentages (ie, missing data points were excluded from both the numerator and denominator in the computation).
| percentage of participants | B/F/TAF |
|---|---|
| Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24, as Analyzed by Missing = Excluded Approach | 100.0 |
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using missing = excluded approach. In this approach, all missing data were excluded in the computation of the percentages (ie, missing data points were excluded from both the numerator and denominator in the computation).
| percentage of participants | B/F/TAF |
|---|---|
| Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48, as Analyzed by Missing = Excluded Approach | 100.0 |
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 72 was analyzed using missing = excluded approach. In this approach, all missing data were excluded in the computation of the percentages (ie, missing data points were excluded from both the numerator and denominator in the computation).
| percentage of participants | B/F/TAF |
|---|---|
| Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 72, as Analyzed by Missing = Excluded Approach | 100.0 |
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 96 was analyzed using missing = excluded approach. In this approach, all missing data were excluded in the computation of the percentages (ie, missing data points were excluded from both the numerator and denominator in the computation).
| percentage of participants | B/F/TAF |
|---|---|
| Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 96, as Analyzed by Missing = Excluded Approach | 100.0 |
Collected over Adverse Events: First dose of study drug up to last dose plus 30 days (up to Week 102.9); All-Cause Mortality: First dose date up to Week 102.9. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| B/F/TAF | 2/86 (2.3%) | 9/86 (10.5%) | 34/86 (39.5%) |
| Event | B/F/TAF |
|---|---|
| Atrial fibrillationCardiac disorders | 1/86 |
| Cardio-respiratory arrestCardiac disorders | 1/86 |
| Ischaemic cardiomyopathyCardiac disorders | 1/86 |
| Anal abscessInfections and infestations | 1/86 |
| Covid-19 pneumoniaInfections and infestations | 1/86 |
| EndocarditisInfections and infestations | 1/86 |
| Intentional overdoseInjury, poisoning and procedural complications | 1/86 |
| Cerebral haemorrhageNervous system disorders | 1/86 |
| Cerebrovascular accidentNervous system disorders | 1/86 |
| Ischaemic strokeNervous system disorders | 1/86 |
| Event | B/F/TAF |
|---|---|
| BronchitisInfections and infestations | 10/86 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 8/86 |
| HypertensionVascular disorders | 8/86 |
| NasopharyngitisInfections and infestations | 7/86 |
| DiarrhoeaGastrointestinal disorders | 6/86 |
| Urinary tract infectionInfections and infestations | 5/86 |
| SciaticaNervous system disorders | 5/86 |
The Safety Analysis Set included all participants who were enrolled and received at least 1 dose of study drug.
| Age, Continuous(years) | B/F/TAF |
|---|---|
| Mean | 70 ± 3.8 |
| Sex: Female, Male(Participants) | B/F/TAF |
|---|---|
| Female | 11 |
| Male | 75 |
| Race/Ethnicity, Customized(Participants) | B/F/TAF |
|---|---|
| Race — American Indian or Alaska Native | 0 |
| Race — Asian | 0 |
| Race — Black | 1 |
| Race — Native Hawaiian or Pacific Islander | 0 |
| Race — White | 82 |
| Race — Other | 0 |
| Race — Not Permitted | 3 |
| Race/Ethnicity, Customized(Participants) | B/F/TAF |
|---|---|
| Ethnicity — Hispanic or Latino | 12 |
| Ethnicity — Not Hispanic or Latino | 71 |
| Ethnicity — Not Permitted | 3 |
| Region of Enrollment(participants) | B/F/TAF |
|---|---|
| Belgium | 8 |
| France | 28 |
| Italy | 22 |
| Spain | 27 |
| United Kingdom | 1 |
| Human Immunodeficiency Virus-1 Ribonucleic acid (HIV-1 RNA) Category(Participants) | B/F/TAF |
|---|---|
| < 50 copies/mL | 84 |
| ≥ 50 copies/mL | 2 |
| Cluster of Differentiation 4 (CD4) Cell Count(cells/µL) | B/F/TAF |
|---|---|
| Mean | 694 ± 273.6 |
| CD4 Cell Count Category(Participants) | B/F/TAF |
|---|---|
| < 50 cells/µL | 0 |
| ≥ 50 to < 200 cells/µL | 2 |
| ≥ 200 to < 350 cells/µL | 7 |
| ≥ 350 to < 500 cells/µL | 9 |
| ≥ 500 cells/µL | 68 |
1 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy.
Supporting information: Study protocol, Statistical analysis plan
Time frame: 18 months after study completion
Access criteria: A secured external environment with username, password, and RSA code.
Data sharing details ↗ · www.gilead.com
Ran from Mar 2018 to primary completion in Nov 2018, 8 months.
Results were first posted in Dec 2019, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Bictegravir · Emtricitabine · Tenofovir alafenamide